News Sentiment

IMVT sentiment intelligence

Immunovant Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 39.71 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+2.4% over one week, +18.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Form 4 Immunovant Inc For: 10 July By Investing.com

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 2.4% Price confirming higher
Trend fit Trend active 18.1% over four weeks
Fair value 50.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 37
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
Investing.com 9
Moomoo 4
simplywall.st 4
Investing.com Canada 2
Finviz 2
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 16
Analyst action 5
Deals and strategy 2
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Investing.com Nigeria Direct company coverage

Form 4 Immunovant Inc For: 10 July By Investing.com

This article from Investing.com announces the filing of a Form 4 for Immunovant Inc. on July 10th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by

Tone
Negative 30/100
Event
Market update
Published
11 Jul 2026 17:10
Source
Investing.com Nigeria
Investing.com Direct company coverage

Immunovant CTO Jay Stout sells $137,924 in IMVT stock

Immunovant's CTO, Jay Stout, sold 3,487 shares of IMVT stock totaling $137,924. These were "sell to cover" transactions to meet tax obligations from vested restricted stock units, not discretionary sales. The stock has seen a significant 135% gain over the past year, though Inves

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 05:09
Source
Investing.com
Investing.com Direct company coverage

Immunovant chief legal officer Van Tuyl sells $47,702 in stock

Immunovant's Chief Legal Officer, Christopher Van Tuyl, recently sold 1,206 shares of company stock for a total of $47,702 to cover tax withholding obligations related to restricted stock units. Following these transactions, Van Tuyl still holds 179,391 shares. The stock has seen

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:09
Source
Investing.com
Investing.com Direct company coverage

Immunovant COO Melanie Gloria sells $80,531 in shares

Immunovant COO Melanie Gloria sold $80,531 worth of company common stock on July 8, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Ms. Gloria directly holds 222,357 shares. The sale occurred while Immunov

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:09
Source
Investing.com
Stock Titan Direct company coverage

Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding

Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, sold 2,036 shares of common stock on July 8, 2026. These sales were not discretionary but were mandated "sell to cover" transactions to meet tax withholding obligations from the vesting of restricted stock units (RSUs).

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Immunovant (IMVT) CTO offloads 3,487 shares in mandated RSU tax-withholding sales

Immunovant's Chief Technology Officer, Jay S. Stout, sold 3,487 shares of IMVT common stock on July 8, 2026. These sales were non-discretionary "sell to cover" transactions to meet tax withholding obligations due to the vesting of restricted stock units (RSUs). The sales occurred

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Immunovant (IMVT) legal chief sells 1,206 shares in tax “sell to cover”

Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 1,206 shares of common stock on July 8, 2026, in a mandatory "sell to cover" transaction. This sale, totaling approximately $47,702, was executed to satisfy tax withholding obligations following the vesting of previousl

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:09
Source
Stock Titan
Moomoo Direct company coverage

LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53

LifeSci Capital has reiterated its Buy rating for Immunovant (IMVT.US) and increased its price target for the stock to $53. This indicates a continued positive outlook from the firm regarding Immunovant's financial prospects and market valuation.

Tone
Positive 73/100
Event
Analyst action
Published
10 Jul 2026 05:39
Source
Moomoo
Investing.com Direct company coverage

Immunovant stock hits 52-week high at 39.28 USD

Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year. This surge is fueled by positive results from its Phase 2 rheumatoid arthritis study of IMVT-1402, with analysts from H.C. Wainwright, BofA Securities, and Stifel rai

Tone
Positive 72/100
Event
Earnings
Published
08 Jul 2026 04:40
Source
Investing.com
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (IMVT)

This article analyzes Immunovant Inc. (IMVT) using AI-generated signals, indicating a strong overweight bias across all time horizons. It provides detailed trading strategies for different risk profiles, including position, momentum breakout, and risk hedging, along with multi-ti

Tone
Positive 77/100
Event
Market update
Published
08 Jul 2026 04:40
Source
Stock Traders Daily
Investing.com South Africa Direct company coverage

Immunovant stock hits 52-week high at 39.28 USD By Investing.com

Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year and achieving a market capitalization of $8.01 billion. This surge is supported by positive analyst ratings and promising results from its Phase 2 rheumatoid arthritis

Tone
Positive 73/100
Event
Earnings
Published
07 Jul 2026 23:40
Source
Investing.com South Africa
AD HOC NEWS Direct company coverage

Immunovant Inc outlines its autoimmune drug pipeline as investors watch clinical milestones

Immunovant Inc is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases using targeted antibody inhibition. The company's pipeline includes treatments for neuromuscular disorders and dermatologic autoimmune diseases, with development h

Tone
Positive 64/100
Event
Market update
Published
07 Jul 2026 14:13
Source
AD HOC NEWS
Stock Titan Direct company coverage

Immunovant (IMVT) CEO settles CVARs with small tax-related share sale

Immunovant, Inc. CEO Eric Venker reported the settlement of 92,188 vested capped value appreciation rights (CVARs) into common stock on July 1, 2026, after meeting service, performance, and knock-in conditions. Concurrently, he disposed of 86,629 shares to the issuer and sold 3,0

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 04:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Immunovant CEO Eric Venker sells $118,980 of IMVT stock By Investing.com

Immunovant CEO Eric Venker recently sold 3,092 shares of Immunovant (NASDAQ:IMVT) common stock for approximately $118,980. This "sell to cover" transaction was executed to fulfill tax withholding obligations tied to the vesting of Capped Value Appreciation Rights (CVARs). The sal

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 04:09
Source
Investing.com Canada
Investing.com Direct company coverage

Immunovant CEO Eric Venker sells $118,980 of IMVT stock

Immunovant CEO Eric Venker sold 3,092 shares of company common stock worth $118,980 to cover tax withholding obligations related to the vesting of Capped Value Appreciation Rights (CVARs). The transaction occurred on July 2, 2026, with the shares sold at $38.48 each. Following th

Tone
Positive 64/100
Event
Market update
Published
06 Jul 2026 22:13
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Immunovant Inc For: 6 July By Investing.com

This article announces the filing of a Form 4 for Immunovant Inc. on July 6. Form 4 filings typically report changes in beneficial ownership of a company's securities by insiders. The article provides the title of the filing but no further details about its content.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:09
Source
Investing.com Canada
Finviz Direct company coverage

IMVT - Immunovant Inc Revenue Breakdown

This article provides a detailed financial overview of Immunovant Inc. (IMVT), covering key metrics such as market cap, income, sales, stock performance, and analyst recommendations. It highlights the company's valuation ratios, insider and institutional ownership, and profitabil

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 11:09
Source
Finviz
Sahm Direct company coverage

Chief Technology Officer Of Immunovant Sold 53% Of Their Shares

Immunovant Inc.'s Chief Technology Officer, Jay Stout, recently sold US$1.5 million worth of stock, representing 53% of his holding. While insider selling at the current price isn't as concerning as selling at a lower price, there has been no insider buying in the last year. Insi

Tone
Negative 36/100
Event
Market update
Published
04 Jul 2026 03:39
Source
Sahm
Finviz Direct company coverage

IMVT - Immunovant Inc Options

This page provides a detailed financial overview of Immunovant Inc (IMVT), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, insider and institutional ownership, profitability metr

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 02:39
Source
Finviz
Moomoo Direct company coverage

Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing

An insider at Immunovant recently sold shares valued at $1,532,309, as disclosed in a recent SEC filing. This transaction could be of interest to investors tracking insider activity within the company. Further details would typically be available in the full SEC document.

Tone
Negative 31/100
Event
Market update
Published
29 Jun 2026 08:13
Source
Moomoo
Investing.com Direct company coverage

Immunovant CTO Jay Stout sells $1.53m in company stock

Immunovant CTO Jay Stout sold 40,000 shares of the company’s common stock for over $1.53 million on June 26, 2026. This sale occurred while Immunovant shares were trading near their 52-week high, with InvestingPro analysis suggesting the stock is overvalued. Despite this insider

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 13:40
Source
Investing.com
Stock Titan Direct company coverage

Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades

Immunovant, Inc. CTO Jay S. Stout reported selling a total of 40,000 shares of the company's common stock in two open-market transactions on June 26, 2026. The shares were sold at weighted average prices of $38.18 and $38.94 per share, totaling approximately $1.53 million. Follow

Tone
Negative 14/100
Event
Market update
Published
27 Jun 2026 11:39
Source
Stock Titan
GuruFocus Direct company coverage

Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I

Melanie Gloria, Chief Operating Officer at a subsidiary of Immunovant Inc (IMVT), sold 17,714 shares of the company on June 26, 2026. Following this transaction, Gloria now owns 224,393 shares. Immunovant Inc is a clinical-stage biopharmaceutical company, and this sale marks part

Tone
Negative 39/100
Event
Market update
Published
27 Jun 2026 02:39
Source
GuruFocus
TradingView Direct company coverage

Price to book forward of Immunovant, Inc. – NASDAQ:IMVT

This article from TradingView focuses on the "Price to book forward" financial metric for Immunovant, Inc. (NASDAQ: IMVT). It is primarily a data page, displaying the period, value, and change for this specific financial indicator related to the biotechnology company. The content

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:13
Source
TradingView
Investing.com Direct company coverage

Immunovant CFO Tiago Girao sells $384,600 in company stock

Immunovant (NASDAQ:IMVT) CFO Tiago Girao sold 10,000 shares of company stock for approximately $384,600 after exercising stock options for the same number of shares. The sale occurred while Immunovant shares were trading near their 52-week high, having delivered a 137% return ove

Tone
Positive 59/100
Event
Market update
Published
27 Jun 2026 00:39
Source
Investing.com
Investing.com Direct company coverage

Immunovant chief legal officer sells $682,886 in stock

Christopher Van Tuyl, Chief Legal Officer at Immunovant, Inc. (NASDAQ:IMVT), sold 17,824 shares of company stock for $682,886 on June 26, 2026, after exercising stock options. The sales occurred while the stock was near its 52-week high, following a significant 137% gain over the

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 00:39
Source
Investing.com